-+ 0.00%
-+ 0.00%
-+ 0.00%

FibroBiologics doses first patients in Phase 1/2 trial of CYWC628 for diabetic foot ulcers

PUBT·06/03/2026 11:01:43
Listen to the news
FibroBiologics doses first patients in Phase 1/2 trial of CYWC628 for diabetic foot ulcers
  • FibroBiologics began dosing patients in a Phase 1/2 trial of CYWC628 for diabetic foot ulcers.
  • No results have been presented; an interim readout is planned once patients complete six weeks of treatment.
  • The study will compare standard of care alone versus standard of care with low or high doses of the topical cell therapy.
  • Outcome focus is safety, tolerability, wound-healing progress, aiming to support CYWC628’s clinical and commercial positioning in chronic wound care.
  • The trial targets up to 120 patients across multiple sites in Australia with treatment lasting up to 12 weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030700PRIMZONEFULLFEED9730967) on June 03, 2026, and is solely responsible for the information contained therein.